Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
4BIO Capital is a London-based venture capital firm established to invest in and support early-stage companies in the advanced therapies sector. Founded with the mission to ensure access to potentially curative therapies for all patients, the firm focuses on addressing high unmet medical needs through innovative treatments. 4BIO Capital primarily operates in Europe and the United Kingdom, targeting companies that develop solutions in cell and gene therapy, RNA-based therapy, targeted therapies, and microbiome-related treatments.
The firm is composed of a diverse team of experts with backgrounds in medicine, finance, and academia, including several PhDs and industry veterans. Although specific fund sizes and portfolio counts are not disclosed, 4BIO Capital is known for its commitment to supporting transformative healthcare solutions. The firm actively seeks to grow its portfolio by identifying viable opportunities that align with its investment thesis.
4BIO Capital's investment strategy is centered on early-stage companies within the advanced therapies sector. The firm specifically targets areas such as cell therapy, gene therapy, RNA-based therapy, targeted therapies, and the microbiome. By focusing on these sectors, 4BIO Capital aims to address significant medical and social needs, ensuring that innovative therapies reach the patients who need them most.
The firm invests at the pre-seed, seed, and seed-plus stages, providing essential funding to startups that are developing groundbreaking treatments. 4BIO Capital seeks high-quality opportunities that demonstrate potential for significant impact in the healthcare landscape. Their approach emphasizes collaboration with founders to enhance the development of their portfolio companies.
4BIO Capital has invested in several notable companies within the advanced therapies sector. Key portfolio companies include:
These investments reflect 4BIO Capital's commitment to supporting innovative companies that are addressing critical healthcare challenges.
Philippe Fauchet OBE, Venture Partner, Japan - Philippe has extensive experience in the biotech sector and has held various leadership roles in international companies.
Vasily Fedorin PhD, Chief Operating Officer - Vasily brings a strong academic background and operational expertise to the firm.
Andrew Kozlov MBA, Managing Partner - Andrew has a proven track record in venture capital and has led numerous successful investments in the biotech space.
Dima Kuzmin PhD, Managing Partner - Dima specializes in advanced therapies and has significant experience in the healthcare industry.
Edward McGill FCA, Financial Controller - Edward oversees financial operations and ensures compliance with regulatory standards.
Alexander McKenna PhD, Investment Associate - Alexander focuses on identifying promising investment opportunities in the biotech sector.
Kieran Mudryy LLB, Partner - Kieran has a legal background and provides insights on regulatory matters affecting portfolio companies.
Natalie Johnston PhD, Investment Principal - Natalie specializes in evaluating scientific and technical aspects of potential investments.
Shikin Gani, Executive Assistant - Shikin supports the team with administrative tasks and coordination.
Jack Shea-Firth PhD, Investment Analyst - Jack conducts market research and analysis to inform investment decisions.
Owen Smith CPFA, Partner - Owen has expertise in financial management and investment strategy.
To pitch 4BIO Capital, founders should email their pitch deck to info@4biocapital.com. The deck should include details about the business model, market opportunity, and team qualifications. A prompt response is typically expected, but timelines may vary based on the volume of inquiries.
4BIO Capital has been active in the investment landscape, with notable portfolio developments. Recently, Trogenix secured £70 million in Series A financing for its clinical development of therapies for aggressive cancers. Additionally, Actithera co-led an oversubscribed $75.5 million Series A financing round, showcasing the firm's ability to attract significant capital for its portfolio companies.
Furthermore, Araris Biotech announced its acquisition by Taiho Pharmaceutical for up to USD 1.14 billion, marking a significant exit for 4BIO Capital and highlighting the potential of its investments in the advanced therapies sector.
What are 4BIO Capital's investment criteria?
4BIO Capital focuses on early-stage companies in the advanced therapies sector, particularly in cell therapy, gene therapy, RNA-based therapy, targeted therapies, and the microbiome. The firm seeks to invest in companies that address significant medical and social needs.
How can I pitch to 4BIO Capital?
Founders can reach out to 4BIO Capital via email at info@4biocapital.com. It is advisable to include a detailed pitch deck that outlines the business model, market opportunity, and team background.
What makes 4BIO Capital different from other investors?
4BIO Capital specializes in advanced therapies and has a strong focus on addressing high unmet medical needs. Their team includes experts with diverse backgrounds, which enhances their ability to support portfolio companies effectively.
What is the geographic focus of 4BIO Capital?
The firm primarily invests in companies located in Europe and the United Kingdom, aligning with its mission to support innovative healthcare solutions in these regions.
What is the typical check size for investments?
While specific check sizes are not disclosed, 4BIO Capital invests at the pre-seed, seed, and seed-plus stages, indicating a focus on early funding rounds.
What kind of support does 4BIO Capital provide to portfolio companies?
4BIO Capital offers operational support, mentorship, and access to a network of industry experts to help portfolio companies grow and succeed in the competitive biotech landscape.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.